Direct Import Expo: Injecting Development Momentum into the Innovative Drug Market in China, for China, and Continuously -- Interview with Dong Lijun, Vice President of ABV
嫦娥的情人矩
发表于 2023-11-7 15:18:42
1279
0
0
Xinhua Finance and Economics Shanghai, November 7th (Reporter Hu Jiefei) - At the 6th China International Import and Export Expo, research-oriented biopharmaceutical company Aibowei joined forces with its subsidiary Aierjian Aesthetics Third to enter the Expo. From "images" to "medicine boxes" and then to entering "medical insurance reimbursement forms", Aberville's innovative drugs are both witnesses and beneficiaries of the development of the Chinese market.
During an interview with reporters, Dong Lijun, Vice President and General Manager of Aberville China, stated that after ten years of deep cultivation in China, Aberville has entered the era of Aberville China 2.0. With the help of the high-level "big stage" of opening up to the outside world, Aberville will work with various partners such as the government, enterprises, academic units, and associations to jointly build, build, and share the medical innovation ecosystem, Jointly explore better ways to solve disease problems and fulfill the long-term commitment of "putting patients at the center".
This year is Aberdeen's third participation in the CIIE. In the previous two events, we brought many innovative products that were the world's first and China's first to the CIIE, and both of them achieved great results. "Dong Lijun said, for example, during the 2020 CIIE, Aberdeen brought two debut products, namely Ruifu (Upatini) and Weikelai (Vineca). These two products were not yet approved when they participated in the CIIE that year, but can only be approved after the CIIE that year, while Ruifu was approved in 2022. Afterwards, these two products were included in the national medical insurance program in January of this year.
It is worth mentioning that the approval of the above products largely depends on the "Chinese speed" and also benefits from the China International Fair. Taking Ruifu as an example, in 2022, it was approved with three indications within one and a half months, and these three indications were included in medical insurance in 2023; In 2023, this product was approved for four new indications, two of which were approved before the end of June, and the other two were approved before entering the Expo. That is to say, Ruifu currently has a total of 7 indications, covering rheumatoid arthritis, ankylosing spondylitis, radiation negative axial spinal arthritis, ulcerative colitis, Crohn's disease, etc. Within 20 months, 7 indications were approved, reflecting both the company's recognition of the Chinese market and its strong attractiveness.
Currently, the innovative drug market in China is experiencing new changes. In Dong Lijun's view, it is clear that Aberdeen is more deeply aware than ten years ago that China, as the world's second largest pharmaceutical market, has great potential for development. Currently, China is entering a stage of upgrading pharmaceutical consumption, and the adjustment of population structure has also brought new opportunities to innovative pharmaceutical companies.
In recent years, in the Huabu Bureau, we have seen that many pharmaceutical companies have achieved some expected results of increased layout while bringing more drugs to Chinese patients. At the time of its establishment, ABV only had three to four hundred people, and its products were relatively single, with relatively small revenue in China. However, we are constantly increasing our research and development investment. Currently, there are 200 R&D personnel, including other employees. Currently, ABV's Pharmaceuticals and Erjian Aesthetics have one There are over two thousand employees in total Dong Lijun said that since the second half of last year, more and more cross-border exchanges have strengthened Aberdeen's confidence in deep cultivation in China.
Dong Lijun said that in the future, ABV will continue to base itself in Shanghai and deeply cultivate China. With the help of the CIIE platform and spillover effects, we will bring more innovative products and treatment plans to China. At the same time, we are committed to bringing more Chinese clinical experience and knowledge to the world. Alberto plans to launch over 30 new products or indications in China by 2030, with nearly 70 ongoing and planned clinical research projects, fully accelerating the meeting of the huge clinical needs of Chinese patients.
CandyLake.com 系信息发布平台,仅提供信息存储空间服务。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
猜你喜欢
- Rockwell Automation Global Senior Vice President: China leads the world in achieving sustainable development
- Starbucks adjusts leadership structure in China, with Liu Wenjuan appointed as CEO of Starbucks China
- Starbucks China changes its style! Liu Wenjuan appointed as CEO to tackle challenges of declining performance
- Be optimistic about the Chinese stock market! Foreign institutions gradually issue Chinese stock funds to buy A-shares at the bottom
- NIO and Sinopec reach charging service cooperation agreement
- NIO and Sinopec reach charging service cooperation agreement
- 28 productions from iQiyi have been shortlisted for the 34th China TV Drama "Flying Apsaras Award"
- Yum China and Poly Developments Establish Strategic Partnership
- Ye Guofu re imagines the future of Chinese retail
- Global funds compete to purchase Chinese assets: why not buy in the future!
-
AIエクスプレスによると、10月3日、米株の人気の中概株盤の前が低くなり、ピッピッピッと5%近く下落し、相多、名創優品、小鵬自動車は3%超下落し、百度、蔚来自動車、京東は2%超下落した。 ...
- SOGO
- 前天 17:06
- 支持
- 反对
- 回复
- 收藏
-
ナスダック中国の金龍指数は5%超上昇し、楽しい自動車は120%超上昇し、金山雲は18%超上昇し、ピシャリと12%超上昇し、子牛の電動、怪獣の充電は10%超上昇し、愛奇芸は8%超上昇し、テンセント音楽、新東方は7%超上昇 ...
- hecgdge4
- 前天 10:28
- 支持
- 反对
- 回复
- 收藏
-
10月1日、理想自動車が9月に納入したデータによると、9月に理想自動車が新車53709台を納入し、前年同月比48.9%増となった。 今年第3四半期、理想自動車は前年同期比45.4%増の152831台を納入した。今年9月30日現在、 ...
- 就放荡不羁就h
- 3 天前
- 支持
- 反对
- 回复
- 收藏
-
EUが中国の電気自動車に関税を課す方針、独首相と財務相が反発 ドイツ連邦のショルツ首相は現地時間の10月2日、EUが中国の電気自動車に一時的な補助金税を課す紛争を解決するために中国と交渉することを表明した。 ...
- 寒郁轩良
- 昨天 10:13
- 支持
- 反对
- 回复
- 收藏